This protocol addresses patients with multiple myeloma who present with MM-related renal impairment — a clinically significant complication that directly shapes the selection and structure of frontline therapy.
Renal impairment caused by multiple myeloma requires specific therapeutic adaptation from the outset. Its presence influences not only which regimens can be used, but also transplant eligibility considerations and the intensity of certain treatment components throughout the course of therapy.
A bortezomib-based regimen combined with daratumumab is the cornerstone of treatment in this setting. Regimen selection is further guided by transplant eligibility, and certain components of therapy may be modified if renal function improves during treatment. The complete regimen options, sequencing, and transplant-related considerations are detailed in the full protocol.
DOI: 10.1038/s41571-025-01041-x